BioCrine

BioCrine is a Swedish biotechnology company dedicated to developing innovative therapies for diabetes and metabolic disorders. Spun out of the Karolinska Institutet, the company's research is centered on the endocrine pancreas and the mechanisms of hormone release from the islets of Langerhans. BioCrine utilizes its proprietary InSight Technology, which involves transplanting pancreatic cells into the anterior chamber of the eye to enable real-time, non-invasive monitoring of cellular function and drug efficacy. The company's therapeutic pipeline includes programs targeting Apolipoprotein C-III, insulin receptor isoforms, and calcium channels, primarily in the pre-clinical stage. BioCrine's approach combines precision medicine with advanced imaging to identify and validate new drug targets for both Type 1 and Type 2 diabetes. The company was acquired by BioStratum in 2024 and continues to operate from its headquarters in Solna, Sweden.